Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction.
The protective effect of dual antiplatelet therapy (DAPT) following acute coronary syndrome is undisputed, but its duration is subject of debate. Several studies show that prolonged therapy provides a clinical benefit in patients following acute coronary syndrome. The aim of this position paper authored by Austrian experts is to outline the current evidence and provide an overview of recent studies. It is also intended to serve as a practical guide to identify those patients who may benefit from prolonged DAPT.
3rd Medical Department of Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria. thomas.weiss@meduniwien.ac.at.
Thomas W
TW
Weiss
Internal Department 2 - Cardiology, Angiology and Internal Intensive Medicine, Krankenhaus der Elisabethinen Linz, Linz, Austria.
Josef
J
Aichinger
3rd Medical Department of Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria.
Kurt
K
Huber
Clinical Department of Cardiology, University Clinic of General Medicine II, Medical University of Vienna, Vienna, Austria.
Walter S
WS
Speidl
Department of General Medicine, Landeskrankenhaus Feldbach, Feldbach-Fürstenfeld Hospital Group, Feldbach, Austria.
Norbert
N
Watzinger
Department of Cardiology, Medical University of Graz, Graz, Austria.
Robert
R
Zweiker
University Clinic of General Medicine III at the Medical University of Innsbruck, Reha-Zentrum Münster, Tyrol and Karl Landsteiner Institute for Interdisciplinary Research at the Reha-Zentrum Münster, Münster/Tyrol, Austria.
Hannes F
HF
Alber
D001241:Aspirin / Q000008:administration & dosage* / Q000592:standards; D001317:Austria; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000592:standards; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000592:standards; D017410:Practice Guidelines as Topic; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage* / Q000592:standards; D055502:Secondary Prevention / Q000592:standards*; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D001241:Aspirin
Acute coronary syndrome; DAPT; Myocardial infarction; P2Y12 inhibitor; Ticagrelor